

Date: 19/10/2024

To,
The Manager,
Listing Department,
Bombay Stock Exchange (BSE)
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 524764

Subject: Outcome of Board Meeting held on October 19, 2024.

Dear Sir/Ma'am,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Nutraplus India Limited ('the Company') at its meeting held today, i.e., October 19, 2024, has approved the Quarterly Financial Results with the Limited Review Report for the quarter ended December 31, 2022.

The aforesaid Financial Results and Reports are enclosed herewith.

The meeting of the Board of Directors commenced at 3.30 p.m. and concluded at 6.30 p.m.

This is for your information and records.

Yours Faithfully

For Nutraplus India Limited

Mukesh Naik
Managing Director
DIN: 00412896

**RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari,B.Com ,F.C.A.



Independent Auditor's Limited review report on unaudited quarterly standalone financial results of NUTRAPLUS INDIA LIMITED for the quarter ended on 31st December,2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015, as amended.

To,

The Board of Directors,
NUTRAPLUS INDIA LIMITED
326-A, Pioneer Eyelets Mfg. Co. Ltd.
Subhash Road Jogeshwari (East),
Mumbai, 400060

1. We have reviewed the accompanying statement of unaudited financial results of NUTRAPLUS INDIA LIMITED ("the Company") for the quarter ended 31st December,2022
2. , being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
3. **Qualified Limited Review Report**
Based on our review, *except for the possible effects of the matters as described in the paragraph 4 Basis for Qualified Limited Review Report below*, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Head Office :- Sam Plaza,'A' Wing,IInd Floor,H.K.Irani Road,Dahanu Road (W) 401602

Branch Office:-

- 1)A-104,1st Floor,Inder Darshan Building,Jamli Gali,Borivali(W),Mumbai(W),400092
- 2)118-121,1st Floor,"Harmony Plaza",Tarapur Road,Boisar,401501

**RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari,B.Com ,F.C.A.



4. Basis for Qualified Limited Review Report

The Company has not complied with the listing requirements under the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically regarding the submission of its limited review report and quarterly results within the prescribed timelines. Furthermore, certain financial data and information necessary to perform the limited review have not been provided by the Company in a timely manner, leading to significant delays in the preparation and review of the quarterly financial results. Due to these issues, our ability to perform a comprehensive review as required under the relevant standards and regulations has been significantly impaired.

5. Emphasis of Matter

We draw attention to **Note 5 of the Statement**, which describes the company lost all its property, plant and equipments under SARFEASI Act,2002 as the company was declared Non Performing Assets in FY-2019-20 and owing to the COVID-19, the bank's procedure for auction was delayed. The delay in the submission of quarterly financial results is attributable to operational disruptions caused by the COVID-19 pandemic and the subsequent auctioning of the company's property, plants, and equipment under the SARFAESI Act, 2002. These extraordinary circumstances significantly impacted the company's ability to finalize and submit its financial statements within the stipulated timeline. Our opinion is not modified in respect of this matter.

6. Other Matters

The statement includes the financial results for the quarter ended 31st December,2022, which is part of the required quarterly financial disclosure, and there has been a delay in submitting these results in accordance with the prescribed listing agreement rules. Our conclusion is not modified in respect of this matter.

For RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 119891W

CA BHARAT C. BHANDARI
Partner
Membership No :- 106122
Place : Mumbai
Date : 19th October,2024
UDIN:- 24106122BKAETL1654

Head Office :- Sam Plaza,'A' Wing,IInd Floor,H.K.Irani Road,Dahanu Road (W) 401602
Branch Office:-
1)A-104,1st Floor,Inder Darshan Building,Jamli Gali,Borivali(W),Mumbai(W),400092
2)118-121,1st Floor,"Harmony Plaza",Tarapur Road,Boisar,401501

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(Rs In Lacs, except per share data)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2022	31-12-2021	30-09-2022	31-12-2022	31-12-2021	31-03-2022
		(Unaudited)			(Unaudited)		Audited
1	Income						
	Revenue from Operations (Net of Taxes)	-	-	-	-	9.80	9.80
	Other Income	-	-	-	-	60.68	62.03
	Total Income from Operations	-	-	-	-	70.48	71.84
2	Expenses						
	a) Cost of Material Consumed	-	-	-	-	-	178.55
	b) Changes in inventories of finished goods & work in progress	-	-	-	-	-	173.78
	c) Employee Benefit Expenses	0.36	0.12	0.82	1.54	1.09	1.09
	d) Finance Cost	0.00	-	2.56	2.57	0.00	0.02
	e) Depreciation and Amortisation Expenses	-	-	-	-	-	-
	f) Other Expenditure	0.71	0.46	7.61	8.80	2.15	21.52
	Total Expenditures	1.07	0.58	11.00	12.90	3.25	374.97
3	Profit/(Loss) from Operations before Exceptional & Extra Ordinary Items & Tax (1-2)	(1.07)	(0.58)	(11.00)	(12.90)	67.24	(303.13)
4	Exceptional Items	-	-	-	-	-	-
5	Profit from Ordinary Activities Before Tax (3-4)	(1.07)	(0.58)	(11.00)	(12.90)	67.24	(303.13)
6	Tax Expense						
	a. Current Year	-	-	-	-	-	-
	b. Deferred Tax	-	-	-	-	-	-
	c. MAT Credit Entitlement	-	-	-	-	-	-
	Total Tax	-	-	-	-	-	-
7	Net Profit/(Loss) from Ordinary Activities after Tax (5-6)	(1.07)	(0.58)	(11.00)	(12.90)	67.24	(303.13)
8	Extraordinary Items (Net of Tax Expenses)	-	-	-	-	-	-
9	Net Profit/(Loss) for the period (7-8)	(1.07)	(0.58)	(11.00)	(12.90)	67.24	(303.13)
10	Other Comprehensive Income						
	Items that will not be reclassified to Profit & Loss						
	Remeasurements of net defined benefits plans (Net of Tax)	-	-	-	-	-	-
	Total Comprehensive Income (9+10)	(1.07)	(0.58)	(11.00)	(12.90)	67.24	(303.13)
11	Earning Per equity Share of face value of Rs.5/- each						
	Basic & Diluted	(0.00)	(0.00)	(0.03)	(0.04)	0.20	(0.89)

Notes:

- 1 The Unaudited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standard (IND AS) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th October, 2024, Limited Review of the same has been carried out by the Statutory Auditors of the Company in term of Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations 2015.
- 3 The figures for the corresponding periods have been regrouped / rearranged wherever necessary for comparison purpose.
- 4 The Company's operations fall under a single segment i.e. Active Pharmaceutical Ingredient (API).
- 5 The Company lost all its property, plants & equipments under SARFAESI ACT, 2002, as Company was declared as Non performing Assets in FY 2019-20. Owing to the epidemic COVID-19, the bank procedure for auction of said assets was delayed, however bank could succeed. The delay in the submission of quarterly financial results is attributable to operational disruptions caused by the COVID-19 pandemic and the subsequent auctioning of the company's property, plants, and equipment under the SARFAESI Act, 2002. These extraordinary circumstances significantly impacted the company's ability to finalize and submit its financial statements within the stipulated timeline.
- 6 The above results of the Company are also available on the Company's website i.e. www.nutrapiusindia.com as well as on the website of BSE i.e. www.bseindia.com

For & on behalf of the Board

Place: Mumbai
Date: 19th October, 2024

Mukesh D. Naik
Managing Director
DIN No. : 00412896

